Denver News Updates

Nonalcoholic Steatohepatitis Market: Market Insights and Market Trend by DelveInsight

 Breaking News
  • No posts were found

Nonalcoholic Steatohepatitis Market: Market Insights and Market Trend by DelveInsight

February 26
21:20 2021
Nonalcoholic Steatohepatitis Market: Market Insights and Market Trend by DelveInsight

DelveInsight has launched a new report on Nonalcoholic Steatohepatitis Market


Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is an advanced form of nonalcoholic fatty liver disease (NAFLD), caused by the buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis. NASH usually comes under the category of silent diseases that has very few or no symptoms typically because it does not cause any symptoms until it is too late. In the early period, patients did not complain about anything specific. Even with the advancing fibrosis, the disease may not have any specific problems. However, in the later stages, patients may start developing some non-specific symptoms.


The key players elaborated in the Nonalcoholic Steatohepatitis Market report includes Genfit, Intercept Pharmaceuticals, Gilead Sciences, Allergan (Tobira Therapeutics) ,Galmed Pharmaceuticals Ltd., Bristol-Myers Squibb (BMS), Immuron Galectin Therapeutics, Cirius Therapeutics, NGM Biopharmaceuticals, TaiwanJ Pharmaceuticals, And many others


Download Free Report Sample-


The classification of fibrosis stages of NASH is as follows: No Fibrosis (F0), NASH Fibrosis (F1–F3), and NASH Cirrhosis (F4). According to various studies, such as Schuppan et al. (2018), Singh et al. (2014), and others, NASH has been defined to keep progressing from early stages (F0 and F1) to advanced stages (F2–F4) over time. The development of NASH with cirrhosis increases the risk of NASH Decompensated Cirrhosis and ultimately to death.


Nonalcoholic Steatohepatitis Market Key Companies

  • Genfit
  • Intercept Pharmaceuticals
  • Gilead Sciences
  • Allergan (Tobira Therapeutics)
  • Galmed Pharmaceuticals Ltd.
  • Bristol-Myers Squibb (BMS)
  • Immuron
  • Galectin Therapeutics
  • Cirius Therapeutics
  • NGM Biopharmaceuticals
  • TaiwanJ Pharmaceuticals
  • And many others


Nonalcoholic Steatohepatitis Market Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Nonalcoholic Steatohepatitis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake


Browse Report Overview   


Global Nonalcoholic Steatohepatitis Treatment Market

The market for the treatment of Nonalcoholic Steatohepatitis (NASH) is likely to experience significant annual growth over the 2018–2030 study period, as major-market sales are expected to increase by 2030.  


Nonalcoholic Steatohepatitis Market Insights

The treatment of NASH depends on the stage of the disease. Currently, there is no approved therapy for the treatment of NASH, yet doctors prescribe certain off-label drugs (supportive therapies) for its management. Lifestyle modifications are, however, the first line of treatment. Lifestyle modifications include going for weight loss combined with an active exercise program along with a planned diet.


Nonalcoholic Steatohepatitis Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Download Free Report Sample-



Table of content

1. Key Insights

2. Executive Summary of Nonalcoholic Steatohepatitis (NASH)

3. Competitive Intelligence Analysis for Nonalcoholic Steatohepatitis (NASH)

4. Nonalcoholic Steatohepatitis (NASH): Market Overview at a Glance

5. Nonalcoholic Steatohepatitis (NASH): Disease Background and Overview

6. Patient Journey

7. Nonalcoholic Steatohepatitis (NASH) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Nonalcoholic Steatohepatitis (NASH) Treatment

11. Marketed Products

12. Emerging Therapies

13. Nonalcoholic Steatohepatitis (NASH): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Nonalcoholic Steatohepatitis (NASH)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight


Enquire about Nonalcoholic Steatohepatitis Market Report-


About Us

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.


Contact Us:

Shruti Thakur

[email protected]


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States